Fuzheng Yiliu Granule (扶正抑瘤颗粒) inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro

Zhi-yun Cao; Xu-zheng Chen; Lian-ming Liao; Jun Peng; Hai-xia Hu; Zhi-zhen Liu; Jian Du

doi:10.1007/s11655-011-0847-3

Your Location：

Home >

Browse articles >

Fuzheng Yiliu Granule (扶正抑瘤颗粒) inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro

Updated：2021-08-27

- Fuzheng Yiliu Granule (扶正抑瘤颗粒) inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro
- Chinese Journal of Integrative Medicine Vol. 17, Issue 9, Pages: 691-697(2011)
- Affiliations：
  
  Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine,Fuzhou,China
- Author bio：
- Funds：
  
  Supported by CHEN Ke-ji Integrative Medicine Development Fund (No. CKJ2010020);International Science Joint Project of the Ministry of Science and Technology of the People's Republic of China (No. 2008DFA32200);Project of Department of Education of Fujian Province (No. JA09136)
- DOI：10.1007/s11655-011-0847-3
  CLC：
- Published：2011，
  
  Published Online：11 September 2011，
Scan for full text
Cao, Zy., Chen, Xz., Liao, Lm. et al. Fuzheng Yiliu Granule (扶正抑瘤颗粒) inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro, ., Chin. J. Integr. Med. 17, 691 (2011). https://doi.org/10.1007/s11655-011-0847-3

Zhi-yun Cao, Xu-zheng Chen, Lian-ming Liao, et al. Fuzheng Yiliu Granule (扶正抑瘤颗粒) inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro. [J]. Chinese Journal of Integrative Medicine 17(9):691-697(2011)
Cao, Zy., Chen, Xz., Liao, Lm. et al. Fuzheng Yiliu Granule (扶正抑瘤颗粒) inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro, ., Chin. J. Integr. Med. 17, 691 (2011). https://doi.org/10.1007/s11655-011-0847-3 DOI：

Zhi-yun Cao, Xu-zheng Chen, Lian-ming Liao, et al. Fuzheng Yiliu Granule (扶正抑瘤颗粒) inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro. [J]. Chinese Journal of Integrative Medicine 17(9):691-697(2011) DOI： 10.1007/s11655-011-0847-3.

摘要

To study the inhibitory effect of Fuzheng Yiliu Granule (扶正抑瘤颗粒

FYG) on hepatocellular cancer (HCC) and investigate the mechanism mediating its bioactivity. H22 tumor-bearing ICR mice were treated with FYG [3.6 g/(kg·d)] for 5 days. Tumor volume and tumor weight

percentages of CD3+

CD4+

CD8+

and natural killer (NK) cells in peripheral blood

tumor apoptosis and serum levels of interleukin-2 (IL-2)

and tumor necrosis factor-α (TNF-α) were evaluated. FYG-containing serum was prepared from SD rats treated for 7 days [high dose 3.6 g/(kg·d); middle dose 1.8 g/(kg·d); low dose 0.9 g/(kg·d)]. Cell cycle

cell viability

and apoptosis were evaluated after HepG2 cell line was cultured in FYG-containing serum for 48 h. The levels of IL-2 and TNF-α in FYG-containing serum were also determined. FYG produced a potent antitumor effect (P<0.01) and induced marked apoptosis of the tumor tissue (P<0.05). Mice treated with FYG had higher percentages of CD3+ and CD4+ (P<0.05)

and more NK cells (P<0.01) in the peripheral blood than those in the animals treated with normal saline. Mice receiving FYG had the highest serum levels of IL-2 and TNF-α (P<0.01). High-dose FYG-containing serum significantly decreased HepG2 cell viability

inhibited cell proliferation (P<0.05)

and induced apoptosis (P<0.01). In addition

the levels of IL-2 and TNF-α of high-dose-containing serum were higher than the blank serum (P<0.01). FYG could inhibit HCC growth by regulating immune function and inducing apoptosis of tumor cells in vivo and in vitro.

Abstract

To study the inhibitory effect of Fuzheng Yiliu Granule (扶正抑瘤颗粒

FYG) on hepatocellular cancer (HCC) and investigate the mechanism mediating its bioactivity. H22 tumor-bearing ICR mice were treated with FYG [3.6 g/(kg·d)] for 5 days. Tumor volume and tumor weight

percentages of CD3+

CD4+

CD8+

and natural killer (NK) cells in peripheral blood

tumor apoptosis and serum levels of interleukin-2 (IL-2)

cell viability

inhibited cell proliferation (P<0.05)

and induced apoptosis (P<0.01). In addition

关键词

Fuzheng Yiliu Granulehepatocellular cancerimmune functionapoptosis

Keywords

Fuzheng Yiliu Granulehepatocellular cancerimmune functionapoptosis

references

Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–1917.

Gish RG, Baron A. Hepatocellular carcinoma (HCC): current and evolving therapies. Drugs 2008; 11:198–203.

Ye SL. Current aspects on standard therapy for primary hepatocellular carcinoma. Chin J Hepatol (Chin) 2008;16:1–2.

Beaugrand M, N'Kontchou G, Seror O, Ganne N, Trinchet JC. Local/regional and systemic treatments of hepatocellular carcinoma. Semin Liver Dis 2005; 25:201–211.

Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellularcar cinoma. Gastroenterology 2004; 127:179–188.

Huang CF, Lin SS, Liao PH, Young SC, Yang CC. The immunopharmaceutical effects and mechanisms of herb medicine. Cell Mol Immunol 2008;5:23–31.

Chen LW, Lin J, Chen W, Zhang WP. Effect of Chinese herbal medicine on patients with primary hepatic carcinoma in III stage during perioperational period: a report of 42 cases. Chin J Integr Tradit West Med (Chin) 2005;25:832–834.

Li L, Chen X, Li J. Observations on the long-term effects of “yi qi yang yin decoction” combined with radiotherapy in the treatment of nasopharyngeal carcinoma. J Tradit Chin Med 1992;12:263–266.

Xu HD, You CG, Zhang RL, Gao P, Wang ZR. Effects of Astragalus polysaccharides and astragalosides on the phagocytosis of mycobacterium tuberculosis by macrophages. J Int Med Res 2007;35:84–90.

Liu LS, Liu JX, Li CJ. Clinical effect of Yiqi Yangyin Jiedu Decoction in treating patients with advanced non-small cell lung cancer. Chin J Integr Tradit West Med (Chin) 2008;28:352–355.

Lin ZB, Zhang HN. Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 2004;25:1387–1395.

Li J, Xie M, Gan Y. Effect of Xiaochaihu Decoction and different herbal formulation of component on inhibiting H22 liver cancer in mice and enhancing immune function. Chin J Integr Tradit West Med (Chin) 2008;33:1039–1044.

Zheng HG, Piao BK, Hua BJ. Effect of Feiliuping Ointment and its disassembled prescriptions on dendritic cell of mice with transplanted Lewis lung cancer. Chin J Integr Tradit West Med (Chin) 2010;30:1288–1291.

Ma XQ, Shi Q, Duan JA, Dong TT, Tsim KW. Chemical analysis of Radix astragali (Huangqi) in China: a comparison with its adulterants and seasonal variations. J Agric Food Chem 2002;50:4861–4866.

McKenna DJ, Hughes K, Jones K. Astragalus. Int J Integr Med. 2002;4:40–46.

Harriet BL, Efrem KLO. Chinese medicine and cancer care. Altern Therap 2003;9:38–52.

Paterson RR. Ganoderma—a therapeutic fungal biofactory. Phytochemistry 2006;67:1985–2001.

Yang YZ, Jin PY, Guo Q, Wu WZ, Pu SY, Chen HZ, et al. Effect of Astragalus membranaceus on natural killer cell activity and induction of alpha-andgamma-interferon in patients with Coxsackie B viral myocarditis. Chin Med J 1990;103:304–307.

Huang ZQ, Qin NP, Ye W. Effect of Astragalus membranaceus on T-lymphocyte subsets in patients with viral myocarditis. Chin J Integr Tradit West Med (Chin) 1995;15:328–330.

Lindequist U, Niedermeyer THJ, Julich WD. The pharmacological potential of mushrooms. Evidence-based Compl Altern Med 2005;2:285–299.

Liu J, Kurashiki K, Shimizu K, Kondo R. Structure-activity relationship for inhibition of alpha-reductase by triterpenoids isolated from Ganoderma lucidum. Bioorg Med Chem 2006;14:8654–8660.

Li JH, Ronen D, Behrens CK, Krammer PH, Clark WR, Berke G. The regulation of CD95 ligand expression and function in CTL. J Immunol 1998;161:3943–3949.

Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661–670.

Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94–100.

Iwama H, Amagaya S, Ogihara Y. Effect of shosaikoto, a Japanese and Chinese traditional herbal medicinal mixture, on the mitogenic activity of lipopolysaccharide: a new pharmacological testing method. J Ethnopharmacol 1987;21:45–53.

FULL TEXT LINK

More>

Views

719

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Artemisinin as a Chinese medicine, selectively induces apoptosis in pancreatic tumor cell line

Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells

The ethanol extract isolated from Weiqi Decoction (胃祺饮) induces G2/M arrest and apoptosis in AGS cells

Effects of Danshen Injection (丹参注射液) on inhibiting proliferation and inducing apoptosis through down-regulation of mutant JAK2 gene and its protein phosphorylation in human erythroid leukemic cells

Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7

Related Author

No data

Related Institution

Department of Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran

Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran

Department of Anesthesia, Chi-Mei Medical Center, Liouying, Tainan

Department of Nursing, Min-Hwei College of Health Care Management, Tainan

Division of Endocrinology and Metabolism, Kaohsiung Veteran General Hospital Tainan Branch, Tainan

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰